Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer.

Abstract

<b>Purpose:</b> Liquid biopsies allow the tracking of clonal dynamics and detection of mutations during treatment.<b>Experimental Design:</b> We evaluated under blinded conditions the ability of cell-free DNA (cfDNA) to detect <i>RAS</i>/<i>BRAF</i> mutations in the plasma of 42 metastatic colorectal cancer patients treated on a phase Ib/II trial of FOLFOX and dasatinib, with or without cetuximab.<b>Results:</b> Prior to treatment, sequencing of archival tissue detected mutations in 25 of 42 patients (60%), while the cfDNA assay detected mutations in 37 of 42 patients (88%). Our cfDNA assay detected mutations with allele frequencies as low as 0.01%. After exposure to treatment, 41 of 42 patients (98%) had a cfDNA-detected <i>RAS</i>/<i>BRAF</i> mutation. Of 21 patients followed with serial measurements who were <i>RAS/BRAF</i> mutant at baseline, 11 (52%) showed additional point mutation following treatment and 3 (14%) no longer had detectable levels of another mutant allele. Of <i>RAS</i>/<i>BRAF</i> wild-type tumors at baseline, 4 of 5 (80%) showed additional point mutations. cfDNA quantitative measurements from this study closely mirrored changes in CEA and CT scan results, highlighting the importance of obtaining quantitative data beyond the mere presence of a mutation.<b>Conclusions:</b> Our findings demonstrate the development of new <i>RAS</i>/<i>BRAF</i> mutations in patients regardless of whether they had preexisting mutations in the pathway, demonstrating a convergent evolutionary pattern. <i>Clin Cancer Res; 23(16); 4578-91. ©2017 AACR</i>.